New CNBC reporting, here:
. . . .A new survey of doctors may show why drugmaker Merck could be having a tough time growing sales of its controversial vaccine for sexually transmitted disease and cervical cancer.
The results being published in a medical journal shows that slightly more than half of 1,122 Texas physicians don't always recommend their eligible patients get Gardasil.
The vaccine has been especially controversial in Texas where the Governor tried to mandate that certain school-age girls get the expensive series of three shots before the legislature put a stop to it.
Sales of Gardasil fell 18 percent in the second quarter. The head of Merck's vaccine business, 49-year-old Margie McGlynn, just announced her retirement. . . .
5 comments:
As to selling. On Cafepharma yesterday there were posts that late Tuesday afternoon and evening offers were made for neuroscience sales jobs. Plus additional interviews would take place today.
Now that's 3 biz days since the FDA AC meeting on asenapine and based upon how these things work it's still likely going to be another week before an approval letter is sent. So either they're so smug from the AC meeting or something else occurred and someone made a phone call or other (premature) communication from the FDA.
Salmon
I don't know, S/P did the same thing prior to Sugga. Advertised and hired a number of sales reps prior to the non-approval letter.
Though, you still may be right. Who really knows?
Well if they hired and then there was a nonapproval. Then either the first option that they were confident about the approval is correct and they wrong, or there was a preliminary communication and it ultimately turned out to be wrong.
Actually the posts over at CafePharma (at least here on Sunday evening) read a fair bit like those immediately before the FDA non-approval of Bridion. . . .
We shall see.
Namaste
Hey you -- once at 7:32 pm... smiling. Fireworks next.
How 'bout you and the kiddos? Tomorrow?
Post a Comment